Carisma and Moderna Join Forces for New Autoimmune Therapies
Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, has announced an exciting expansion of its collaboration with Moderna, Inc. (NASDAQ: MRNA). Together, they aim to develop innovative in vivo CAR-M therapies for autoimmune diseases. This partnership seeks to harness the cutting-edge technologies of both companies in immunotherapy, representing a significant advancement from their earlier work in oncology.
Collaboration Expansion Details
This collaboration builds on Carisma’s promising pre-clinical in vivo CAR-M data obtained from cancer treatments. As part of the newly expanded agreement, Carisma has pinpointed two specific autoimmune disease targets to focus their joint efforts on. This strategic move allows Carisma to retain all rights for additional autoimmune disease targets beyond the two selected, ensuring a unique alignment with Moderna.
Integration of Innovative Technologies
By combining Carisma's proprietary CAR-M technology with Moderna's advanced mRNA and lipid nanoparticle (LNP) platform, both companies are poised to pioneer new macrophage engineering strategies aimed at these autoimmune targets. Carisma will handle the discovery and optimization of development candidates, while Moderna will oversee clinical development and the eventual commercialization of the therapies that emerge from this collaboration.
Leadership Insights on the Vision
Steven Kelly, President and CEO of Carisma, shared his excitement about this collaboration, stating, "Expanding our work with Moderna into the realm of autoimmune diseases marks a significant milestone in our mission to harness macrophages for treating various illnesses. Our CAR-M technology has the potential to transform the lives of patients facing these challenging conditions." This sentiment is reflected by Lin Guey, PhD, CSO of Therapeutic Research Ventures at Moderna, who remarked, "Building on our advancements in CAR-M therapies with Carisma allows us to extend our reach beyond oncology, and we believe that our combined expertise can lead to meaningful innovations for patients."
Anticipated Impact on Disease Treatment
The collaboration aims to introduce innovative therapies that could significantly benefit a wide range of disease areas, especially cancer and autoimmune diseases. By pushing the boundaries of immunotherapy, this partnership is expected to set new benchmarks in how we approach treatment for various debilitating health conditions.
About Carisma Therapeutics
Carisma Therapeutics is committed to developing advanced immunotherapies through a novel macrophage and monocyte engineering platform. Their mission is to tackle cancer and serious diseases with transformative solutions. By concentrating on engineered macrophages and monocytes, which are crucial in immune responses, Carisma is well-positioned to lead in this innovative therapeutic field. More information about their work can be found on their official website.
Frequently Asked Questions
What is the purpose of the Carisma and Moderna collaboration?
The collaboration aims to develop in vivo CAR-M therapies specifically targeting autoimmune diseases.
What technology is being used in this collaboration?
The partnership combines Carisma's proprietary CAR-M technology with Moderna's mRNA and lipid nanoparticle platform.
What are the roles of Carisma and Moderna in this agreement?
Carisma is responsible for discovering and optimizing drug candidates, while Moderna leads clinical development and commercialization.
How many autoimmune disease targets are being pursued?
The expansion includes the nomination of two specific autoimmune disease targets for detailed development.
What is the expected impact of this collaboration?
The partnership is designed to advance immunotherapy treatment options for patients suffering from cancer and autoimmune diseases.
